United States Biotechnology & Medical Research

BIOAGE Labs Inc (BIOA)

BIOAGE Labs Inc. experienced multiple planned and proposed sales by executives throughout early 2026. The most recent transactions occurred on June 30, 2026, involving officer Shane Barton. No insider trading activity has been recorded within the last three months, indicating a period of inactivity regarding equity movements by company leadership.
Ticker: BIOA
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for BIOAGE Labs Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Barton Shane Principal Accounting Officer Officer
Transaction date
Planned sale
Price
471.54
Quantity 73,643 +14.5%
Value US$3,857,487
Barton Shane Officer Officer
Transaction date
Proposed sale
Price
146.32
Quantity 95,878
Value US$1,227,849
Barton Shane Principal Accounting Officer Officer
Transaction date
Planned sale
Price
372.48
Quantity 20,027 -32.3%
Value US$4,436,827
Barton Shane Officer Officer
Transaction date
Proposed sale
Price
25.21
Quantity 42,350
Value US$1,067,578
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
17.81
Quantity 8,820 -100.0%
Value US$157,084
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
17.81
Quantity 8,820 -100.0%
Value US$157,084
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
17.81
Quantity 8,820
Value US$157,084
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.30
Quantity 7,433 -100.0%
Value US$150,890
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
20.03
Quantity 7,433
Value US$148,883
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.75
Quantity 7,433 -100.0%
Value US$139,369
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.75
Quantity 7,433 -100.0%
Value US$139,369
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
18.75
Quantity 7,433
Value US$139,369
0.6
GOLDSTEIN DOV A MD Chief Financial Officer Officer
Transaction date
Planned sale
Price
21.08
Quantity 1,923 -7.9%
Value US$40,538
0.6
GOLDSTEIN DOV A MD Chief Financial Officer Officer
Transaction date
Planned sale
Price
20.54
Quantity 11,663 -32.4%
Value US$239,549
0.6
GOLDSTEIN DOV A MD Chief Financial Officer Officer
Transaction date
Planned sale
Price
19.45
Quantity 4,440 -11.0%
Value US$86,370
0.6
GOLDSTEIN DOV A MD Chief Financial Officer Officer
Transaction date
Planned sale
Price
18.43
Quantity 8,974 -18.2%
Value US$165,371
Fortney Kristen Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
18.12
Quantity 233,107 -19.3%
Value US$4,223,036
Fortney Kristen 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
18.00
Quantity 233,107
Value US$4,195,926
0.6
GOLDSTEIN DOV A MD Officer Officer
Transaction date
Proposed sale
Price
19.70
Quantity 27,000
Value US$531,828
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.85
Quantity 7,433 -100.0%
Value US$95,490
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
13.41
Quantity 7,433
Value US$99,677
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 18,000 -100.0%
Value US$216,000
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
12.00
Quantity 18,000
Value US$216,000
RUBIN PAUL D Chief Medical Officer Officer
Transaction date
Planned sale
Price
10.19
Quantity 68,897 -100.0%
Value US$701,909
RUBIN PAUL D Officer Officer
Transaction date
Proposed sale
Price
10.19
Quantity 68,897
Value US$701,912
1.7
Pande Vijay Satyanand Non-Executive Director
Transaction date
Purchase
Price
19.90
Quantity 25,306 +2.3%
Value US$503,589
1.7
Pande Vijay Satyanand Non-Executive Director
Transaction date
Purchase
Price
19.73
Quantity 67,096 +6.5%
Value US$1,323,804
1.7
Pande Vijay Satyanand Non-Executive Director
Transaction date
Purchase
Price
19.73
Quantity 126,793 +14.1%
Value US$2,501,626
Barton Shane Principal Accounting Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 2,632 New position
Value US$47,376
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 26,497 New position
Value US$476,946
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 21,814 New position
Value US$392,652
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 18,353 New position
Value US$330,354
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 11,113 New position
Value US$200,034
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 588,888 +35.9%
Value US$10,599,984
3.6
ENRIGHT PATRICK G Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 400,000 +30.5%
Value US$7,200,000
1.7
Pande Vijay Satyanand Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 900,000 New position
Value US$16,200,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-01 2026-06-30 PlS Planned sale
Barton Shane

Principal Accounting Officer

Officer
73,643 +14.5%
471.54
US$3,857,487 		73,643 +14.5% 471.54 US$3,857,487
2026-06-30 2026-06-30 PrS Proposed sale
Barton Shane

Officer

Officer
95,878
146.32
US$1,227,849 		95,878 146.32 US$1,227,849
2026-07-01 2026-06-29 PlS Planned sale
Barton Shane

Principal Accounting Officer

Officer
20,027 -32.3%
372.48
US$4,436,827 		20,027 -32.3% 372.48 US$4,436,827
2026-06-29 2026-06-29 PrS Proposed sale
Barton Shane

Officer

Officer
42,350
25.21
US$1,067,578 		42,350 25.21 US$1,067,578
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
8,820 -100.0%
17.81
US$157,084 		8,820 -100.0% 17.81 US$157,084
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
8,820 -100.0%
17.81
US$157,084 		8,820 -100.0% 17.81 US$157,084
2026-04-01 2026-04-01 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
8,820
17.81
US$157,084 		8,820 17.81 US$157,084
2026-03-03 2026-03-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
20.30
US$150,890 		7,433 -100.0% 20.30 US$150,890
2026-03-02 2026-03-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
20.03
US$148,883 		7,433 20.03 US$148,883
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-02 2026-02-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
18.75
US$139,369 		7,433 18.75 US$139,369
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
1,923 -7.9%
21.08
US$40,538 		1,923 -7.9% 21.08 US$40,538
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
11,663 -32.4%
20.54
US$239,549 		11,663 -32.4% 20.54 US$239,549
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
4,440 -11.0%
19.45
US$86,370 		4,440 -11.0% 19.45 US$86,370
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
8,974 -18.2%
18.43
US$165,371 		8,974 -18.2% 18.43 US$165,371
2026-01-15 2026-01-13 PlS Planned sale
Fortney Kristen

Chief Executive Officer

Executive Director
233,107 -19.3%
18.12
US$4,223,036 		233,107 -19.3% 18.12 US$4,223,036
2026-01-13 2026-01-13 PrS Proposed sale
Fortney Kristen

10% Stockholder

Large shareholder
233,107
18.00
US$4,195,926 		233,107 18.00 US$4,195,926
2026-01-13 2026-01-13 PrS Proposed sale
0.6
GOLDSTEIN DOV A MD

Officer

Officer
27,000
19.70
US$531,828 		27,000 19.70 US$531,828
2026-01-06 2026-01-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
12.85
US$95,490 		7,433 -100.0% 12.85 US$95,490
2026-01-02 2026-01-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
13.41
US$99,677 		7,433 13.41 US$99,677
2025-12-11 2025-12-09 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
18,000 -100.0%
12.00
US$216,000 		18,000 -100.0% 12.00 US$216,000
2025-12-09 2025-12-09 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
18,000
12.00
US$216,000 		18,000 12.00 US$216,000
2025-12-05 2025-12-04 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
68,897 -100.0%
10.19
US$701,909 		68,897 -100.0% 10.19 US$701,909
2025-12-04 2025-12-04 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
68,897
10.19
US$701,912 		68,897 10.19 US$701,912
2024-10-03 2024-10-03 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
25,306 +2.3%
19.90
US$503,589 		25,306 +2.3% 19.90 US$503,589
2024-10-03 2024-10-02 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
67,096 +6.5%
19.73
US$1,323,804 		67,096 +6.5% 19.73 US$1,323,804
2024-10-03 2024-10-01 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
126,793 +14.1%
19.73
US$2,501,626 		126,793 +14.1% 19.73 US$2,501,626
2025-03-10 2024-09-27 B Purchase
Barton Shane

Principal Accounting Officer

Officer
2,632 New position
18.00
US$47,376 		2,632 New position 18.00 US$47,376
2024-10-01 2024-09-27 B Purchase
3.1
Cormorant Asset Management, LP

Former 10% Owner
450,000 +38.2%
18.00
US$8,100,000 		450,000 +38.2% 18.00 US$8,100,000
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
26,497 New position
18.00
US$476,946 		26,497 New position 18.00 US$476,946
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
21,814 New position
18.00
US$392,652 		21,814 New position 18.00 US$392,652
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
18,353 New position
18.00
US$330,354 		18,353 New position 18.00 US$330,354
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
11,113 New position
18.00
US$200,034 		11,113 New position 18.00 US$200,034
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
588,888 +35.9%
18.00
US$10,599,984 		588,888 +35.9% 18.00 US$10,599,984
2024-09-27 2024-09-27 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
400,000 +30.5%
18.00
US$7,200,000 		400,000 +30.5% 18.00 US$7,200,000
2024-09-27 2024-09-27 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
900,000 New position
18.00
US$16,200,000 		900,000 New position 18.00 US$16,200,000
Explore more

More insider trading research around BIOAGE Labs Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America